Skip to main content
Top
Published in: Annals of Surgical Oncology 5/2013

01-05-2013 | Endocrine Tumors

Hereditary Medullary Thyroid Cancer: Age-Appropriate Thyroidectomy Improves Disease-Free Survival

Authors: Kevin Shepet, BS, Amal Alhefdhi, MD, Ngan Lai, BA, Haggi Mazeh, MD, Rebecca Sippel, MD, FACS, Herbert Chen, MD, FACS

Published in: Annals of Surgical Oncology | Issue 5/2013

Login to get access

Abstract

Background

Twenty-five percent of medullary thyroid cancer (MTC) cases are hereditary. The ideal age for prophylactic thyroidectomy is based on the specific RET mutation involved. The purpose of this study was to determine whether such age-appropriate prophylactic thyroidectomy results in improved disease-free survival.

Methods

Twenty-eight patients underwent thyroidectomy for hereditary MTC at our institution. Age-appropriate thyroidectomy was defined according to the North American Neuroendocrine Tumor Society (NANETS) guidelines. Patients who had age-appropriate surgery (group 1, n = 9) were compared to those who had thyroidectomy past the recommended age (group 2, n = 19).

Results

The mean age was 13 ± 2 years, and 61 % were female. Patients in group 1 were younger than in group 2 (4 ± 1 vs. 17 ± 2 years, p < 0.01). There were no significant differences in gender or RET mutation types between these two groups. Group 1 patients were cured with no disease recurrence compared with group 2 patients who had a 42 % recurrence rate (p = 0.05). Subanalysis of group 2 identified that patients who underwent surgery without evidence of disease did so at a shorter period following the guidelines compared with those who underwent therapeutic surgery (2 ± 2 vs. 16 ± 2 years, p = 0.01) and had longer disease-free survival (100 vs. 27 %, p = 0.005).

Conclusions

Patients with hereditary MTC should undergo age-appropriate thyroidectomy based on RET mutational status to avoid recurrence. Patients who are past the recommended age should have surgery as early as possible to improve disease-free survival.
Literature
1.
go back to reference Chen H, Sippel RS, O’Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775–83.PubMedCrossRef Chen H, Sippel RS, O’Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775–83.PubMedCrossRef
2.
go back to reference Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist. 2008;13(5):539–47.PubMedCrossRef Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist. 2008;13(5):539–47.PubMedCrossRef
3.
go back to reference Greenblatt DY, Chen H. Palliation of advanced thyroid malignancies. Surg Oncol. 2007;16(4):237–47.PubMedCrossRef Greenblatt DY, Chen H. Palliation of advanced thyroid malignancies. Surg Oncol. 2007;16(4):237–47.PubMedCrossRef
4.
go back to reference Chen H, Roberts JR, Ball DW, et al. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg. 1998;227(6):887–95.PubMedCrossRef Chen H, Roberts JR, Ball DW, et al. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg. 1998;227(6):887–95.PubMedCrossRef
5.
go back to reference Moley JF, Lairmore TC, Phay JE. Hereditary endocrinopathies. Curr Prob Surg. 1999;36(9):653–762.CrossRef Moley JF, Lairmore TC, Phay JE. Hereditary endocrinopathies. Curr Prob Surg. 1999;36(9):653–762.CrossRef
6.
go back to reference Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet. 2000;37(11):817–27.PubMedCrossRef Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet. 2000;37(11):817–27.PubMedCrossRef
7.
go back to reference Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Mol Genet. 1993;2(7):851–6.CrossRef Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Mol Genet. 1993;2(7):851–6.CrossRef
8.
go back to reference Pinchot SN, Sippel RS, Chen H. Multi-targeted approach in the treatment of thyroid cancer. Ther Clin Risk Manag. 2008;4(5):935–47.PubMed Pinchot SN, Sippel RS, Chen H. Multi-targeted approach in the treatment of thyroid cancer. Ther Clin Risk Manag. 2008;4(5):935–47.PubMed
9.
go back to reference Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19):1575–9.PubMedCrossRef Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19):1575–9.PubMedCrossRef
10.
go back to reference Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene: a review and update of genotype–phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005;15(6):531–44.PubMedCrossRef Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene: a review and update of genotype–phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005;15(6):531–44.PubMedCrossRef
11.
go back to reference Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Eng J Med. 2005;353(11):1105–13.CrossRef Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Eng J Med. 2005;353(11):1105–13.CrossRef
12.
go back to reference O’Riordain DS, O’Brien T, Weaver AL, et al. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery. 1994;116(6):1017–23.PubMed O’Riordain DS, O’Brien T, Weaver AL, et al. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery. 1994;116(6):1017–23.PubMed
13.
go back to reference Schreinemakers JMJ, Vriens MR, Valk GD, et al. Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study. World J Surg. 2010; 34(4):852–60.PubMedCrossRef Schreinemakers JMJ, Vriens MR, Valk GD, et al. Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study. World J Surg. 2010; 34(4):852–60.PubMedCrossRef
14.
go back to reference Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Eng J Med. 2003;349(16):1517–25.CrossRef Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Eng J Med. 2003;349(16):1517–25.CrossRef
15.
go back to reference Wolfe HJ, Melvin KE, Cervi-Skinner SJ, et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N Eng J Med. 1973;289(9):437–41.CrossRef Wolfe HJ, Melvin KE, Cervi-Skinner SJ, et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N Eng J Med. 1973;289(9):437–41.CrossRef
16.
go back to reference Kloos R, Eng C, Evans D, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612.PubMedCrossRef Kloos R, Eng C, Evans D, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612.PubMedCrossRef
Metadata
Title
Hereditary Medullary Thyroid Cancer: Age-Appropriate Thyroidectomy Improves Disease-Free Survival
Authors
Kevin Shepet, BS
Amal Alhefdhi, MD
Ngan Lai, BA
Haggi Mazeh, MD
Rebecca Sippel, MD, FACS
Herbert Chen, MD, FACS
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 5/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2757-9

Other articles of this Issue 5/2013

Annals of Surgical Oncology 5/2013 Go to the issue